Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Stopped Study was halted prematurely due to safety, since tocity stopping rules have been met
Conditions
Interventions
- DRUG: Idelalisib
- DRUG: Obinutuzumab
Sponsor
Fondazione Italiana Linfomi - ETS